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Abstract
Purpose We present a systematic review to evaluate
failure rates (secondary hysterectomy or maternal mortality)
and success rates (subsequent menstruation or pregnancy)
after diVerent uterus preserving treatment modalities in
women with invasive placentation.
Methods A review of English, German or Dutch lan-
guage-published research, using Medline and Embase dat-
abases, was performed. Studies of any design were
included.
Results Ten cohort studies and 50 case series or case
reports were included. Expectant management reported a
secondary hysterectomy in 55/287 (19%), maternal mortal-
ity in 1/295 (0.3%), a subsequent menstruation in 44/49
(90%) and a subsequent pregnancy in 24/36 (67%). Embo-
lization of the uterine arteries described a secondary hyster-
ectomy in 8/45 (18%), a subsequent menstruation in 8/13
(62%) and a subsequent pregnancy in 5/33 (15%). Metho-
trexate therapy presented a secondary hysterectomy in 1/16
(6%), a subsequent menstruation in 4/5 (80%) and a subse-
quent pregnancy in 1/2 (50%). Uterus preserving surgery
showed a secondary hysterectomy in 24/77 (31%), maternal
mortality in 2/55 (4%), a subsequent menstruation in 28/34
(82%) and a subsequent pregnancy in 19/26 (73%).
Conclusions This review indicates that diVerent uterus
preserving treatment modalities may be eVective in manag-
ing invasive placentation. Despite the extensive review of
the literature, no conclusions about the superiority of any
modality can be drawn.
Keywords Invasive placentation · Conservative 
management · Uterus preserving therapy · 
Systematic review
Introduction
Placental implantation in which there is abnormally Wrm
adherence to the uterine wall is deWned as placenta increta
as well as related conditions like placenta accreta and per-
creta [1]. This is a challenging obstetrical problem causing
severe maternal morbidity like uterine perforation, infec-
tion and severe hemorrhage. Severe bleeding is the single
most signiWcant cause of maternal death worldwide [2].
Invasive placentation aVects »2% of all singleton deliver-
ies [3]. Probably due to the increasing rates of caesarean
deliveries in most countries, the incidence has increased in
recent years [4]. Because previous studies reported better
maternal survival with hysterectomy than with uterus pre-
serving treatment modalities, a hysterectomy has long been
the initial therapy [2]. However, preserving uterine function
is important to preserve reproductive potential.
Several case reports indicate that uterus preserving treat-
ment may result in successful management of invasive pla-
centation. In the current literature, diVerent uterus
preserving treatment modalities are described: expectant
management, embolization of the uterine arteries, metho-
trexate therapy and uterus preserving surgery [2, 5, 6]. In
2007, Timmermans et al. [6] reviewed 48 case reports
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492 Arch Gynecol Obstet (2011) 284:491–502about the obstetric outcome after expectant management,
embolization of the uterine arteries and methotrexate ther-
apy for invasive placentation. They concluded that it should
only be considered in highly selected cases and that no
proof was found for a Wrst choice uterus preserving treat-
ment modality.
We present a literature review to evaluate failure rates
(secondary hysterectomy or maternal mortality) and
success rates (subsequent menstruation or pregnancy) after




A computer-aided search of Medline and Embase was
carried out. The following search terms were used: ‘pla-
centa accreta’, ‘placenta increta’, ‘placenta percreta’ and
‘conservative treatment’ (Appendix 1). The reference lists
of identiWed studies were searched for additional relevant
studies.
Inclusion criteria
Every study design that was published in English, German or
Dutch was considered for inclusion. Given that randomized-
controlled trials and large observational cohort studies that
can be used to deWne best practice are lacking, studies of any
design were obtained for further evaluation. Studies were
included if they described the course of uterus preserving
treatment modalities for patients with placenta accreta,
increta or percreta. Uterus preserving treatment modalities
were deWned as initial therapy consisting of: expectant man-
agement (expectant management for patients who delivered
vaginally or closing the hysterectomy as caesarean delivery
occurred), embolization of the uterine arteries, methotrexate
therapy or uterus preserving surgery. Because we investi-
gated uterus preserving techniques in which the placenta was
left in situ, we limited uterus preserving surgery to hemo-
static sutures, arterial ligation and balloon tamponade. Diag-
noses of invasive placentation must be made upon clinical
suspicion, ultrasound or magnetic resonance imaging (MRI).
Studies were excluded if patients underwent a hysterectomy
as initial management, or if patients were approached conser-
vatively because caesarean hysterectomy was considered too
dangerous or diYcult.
Selection of studies
The Wrst reviewer (CN) screened the titles and abstracts of
identiWed articles for eligibility. Papers that seemed to be
relevant were obtained, and the full text articles were
screened for inclusion. If there was doubt about the suit-
ability of the studies, they were discussed with two other
independent reviewers (TP, TE).
Data extraction and analysis
The eligible articles were summarized in a data extraction
form, including the following items: obstetric characteristics,
maternal morbidity/mortality and subsequent pregnancy/
menstruation. Obstetric characteristics included gestational
age and mode of delivery. Maternal morbidity/mortality
was deWned as severe vaginal bleeding (need for blood
transfusion or >1,000 ml blood loss), sepsis (deWnition used
according to the deWnitions of the authors in the diVerent
studies), a secondary hysterectomy or maternal mortality.
Data were presented as numbers and as percentages
(rates). Rates were calculated using the reported number of
a speciWc item as the numerator divided by all studies that
reported that speciWc item as denominator.
Data were summarized separately for expectant manage-
ment, methotrexate therapy, embolization of the uterine
arteries and uterus preserving surgery with distinction
between forms of invasive placentation (placenta accreta,
increta or percreta).
Data extraction and analysis was done by the Wrst
reviewer (CN).
Results
We identiWed 1,477 articles, of which 270 were potentially
relevant after removing duplicates and screening the title
and abstract. Applying our inclusion criteria led to the
inclusion of 10 cohort studies and 50 case series or case
reports describing 434 patients. Of them, 295 patients
treated with expectant management, 45 with embolization
of the uterine arteries, 17 with methotrexate therapy and 77
with uterus preserving surgery were reported (Fig. 1).
Expectant management (Table 1)
Twenty articles described 295 patients with invasive
placentation approached with expectant management [7–26]:
a secondary hysterectomy occurred in 55/287 (19%),
maternal mortality in 1/295 (0.3%), a subsequent
menstruation in 44/49 (90%) and a subsequent pregnancy
in 24/36 (67%).
Embolization of the uterine arteries (Table 2)
Sixteen articles reported 45 patients managed with embo-
lization of the uterine arteries [12, 27–41]: a secondary123
Arch Gynecol Obstet (2011) 284:491–502 493hysterectomy occurred in 8/45 (18%), a subsequent
menstruation in 8/13 (62%) and a subsequent pregnancy
in 5/33 (15%). All patients survived until the end of
follow up.
Methotrexate therapy (Table 3)
Fifteen articles showed 17 patients receiving methotrexate
therapy [22, 42–55]: a secondary hysterectomy occurred in
1/16 (6%), a subsequent menstruation in 4/5 (80%) and a
subsequent pregnancy in 1/2 (50%). All patients from the
studies survived until the end of follow up.
Uterus preserving surgery (Table 4)
Eleven articles presented 77 patients with uterus preserving
surgery [56–66]: a secondary hysterectomy occurred in 24/77
(31%), maternal mortality in 2/55 (4%), a subsequent
menstruation in 28/34 (82%) and a subsequent pregnancy
in 19/26 (73%).
Comment
The aim of the current review was to evaluate failure and
success rates of women with invasive placentation man-
aged with diVerent uterus preserving treatment modali-
ties. The most important gain of uterus preserving
treatment is preserving reproductive material. Our results
show varying failure and success rates among the diVer-
ent uterus preserving treatment modalities: a secondary
hysterectomy was needed in 6–31% and maternal mortal-
ity occurred in 0–4% (failure rates); menstruation fol-
lowed in 62–90% and a subsequent pregnancy occurred
in 15–73% (success rates). Our results are based on
descriptive data only (case series, case reports and a few
cohort studies). Therefore, it is not possible to compare
diVerent uterus preserving treatment modalities and no
conclusions about the superiority of any modality can be
drawn.
Uterus preserving treatment modalities in general
Given the risk of substantial morbidity (including coagu-
lopathy, severe hemorrhage, infection, sepsis, ureteral
injury, need for blood transfusion/hysterectomy) and mor-
tality, uterus preserving treatment may have a role in care-
fully selected patients who desire future fertility [67]. The
patient should be counselled about the risk of hysterec-
tomy, blood transfusion and even death. Prophylactic anti-
biotics are generally administrated to prevent infection
[18]. When conservative management is successful, it
results in gradual resorption of the placenta or delayed
delivery of the placenta [15, 17, 29]. Due to the risk of
severe hemorrhage, all obstetric units and practitioners
must have the facilities, personnel, and equipment in place
to manage this emergency properly and a multidisciplinary
approach is recommended [2, 68].















60 Articles ** 
N= 434
Search updated on April 14th 2011. N: number of patients. 
* using in- and exclusion criteria
** Two articles12,21 described two different uterus preserving approaches 
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Whether adjuvant therapy in addition to expectant manage-
ment alone is beneWcial is uncertain. Timmermans et al. [6]
reported 60 cases with abnormally invasive placentation.
Expectant management was successful in 48 cases, but
adjuvant therapy (uterine arterial embolization and metho-
trexate therapy) was employed in 34 cases.
Uterine arterial embolization
Arterial embolization is a viable treatment for postpar-
tum bleeding. A patient with stable vital sings and per-
sistent bleeding, especially if the rate of loss is not
excessive, may be a candidate for arterial embolization
[2]. A previous Cochrane review [69] compared uterine
arterial embolization with hysterectomy for symptom-
atic uterine Wbroids. They concluded that uterine arterial
embolization oVers an advantage over hysterectomy
with regard to a shorter hospital stay and a quicker
return to routine activities. SpeciWc complications from
this procedure include iliac artery thrombosis, uterine
necrosis or sepsis resulting in multiple organ failure. In
addition, non-target embolization can cause ischaemic
damage to other organs [70].
Methotrexate therapy
Methotrexate disrupts the folic acid pathway in rapidly
dividing cells such as trophoblasts. However, the prolifera-
tion of trophoblasts in the later stages of pregnancy has
been shown to have no role in placental growth [67]. Con-
sequently, the use of methotrexate may not reduce placental
volume. This therapy might even be harmful: methotrexate
has a immunosuppressive role and therefore could increase
the risk of infection or even sepsis, which is already
increased in patients with abnormal adherent placentation.
Other speciWc adverse eVects are methotrexate-related pan-
cytopenia and nephrotoxicity [71, 72].
Uterus preserving surgery
Uterine compression sutures function in a manner similar to
manual compression and are placed to prevent uterine
relaxation due to the retained placenta [73]. Arterial occlu-
sion (arterial ligation or balloon tamponade) is indicated for
the management of bleeding. In some cases, a combination
of both techniques was used [59]. Because we investigated
uterus preserving techniques in which the placenta was left
in situ, we limited uterus preserving surgery to hemostatic
sutures, arterial ligation and balloon tamponade. Other sur-
gical techniques focussing on resection of the invasive pla-
centation are described [74]. In addition to technical
advances in vascular control and tissue repair, these surgi-
cal resection techniques may contribute to future better
uterus preserving surgical options.
Limitations
Due to the descriptive data, this review has a narrative char-
acter. The biggest limitation of descriptive data gathered
from published case reports and series is that these data are
subject to publication bias. The data may be misleading,
giving uterus preserving treatment modalities a higher than
true success rate. People tend to write up case reports of
cases they did that went well; they are less likely to write up
the case report about the patients who died or had major
complications from uterus preserving treatment. Severe
complications are prone to being underreported.
In addition, the cases are limited by the ability to fully
determine correct documentation of correct pregnancy or
long-term outcome/complications of these pregnancies. In
most case reports, data are lacking, which make it diYcult
to draw conclusions.
Furthermore, categorizing each case speciWcally based
upon the type of uterus preserving treatment modality is
diYcult since there are varying degrees of placental
attachment abnormalities and varying amounts of the pla-
centa which adhere abnormally to the uterus. The uterine
preserving treatment modality is a surgical decision based
upon particular characteristics of the problem and the
expertise of the surgeon. The choice of uterus preserving
treatment modality is intricately linked with the degree of
placental volume involved. SpeciWc uterus preserving
treatment modalities may have the best outcome because
the volume of placental involvement is less. Bad out-
comes may be employed in large volume placental
involvement. The results may simply be a function of dis-
ease severity.
However, evaluation of uterus preserving treatment is
important and of great clinical use because of the possi-
bility of a subsequent pregnancy. Large-scale studies are
required using prospective and repeated measure designs
to further evaluate the safety, eYcacy and fertility
eVects.
Conclusion
This review indicates that diVerent uterus preserving treat-
ment modalities may be eVective in managing invasive pla-
centation. Despite the extensive review of the literature, no
conclusions about the superiority of any modality can be
drawn.
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Abstract]) OR “placenta’s”[Title/Abstract])) AND
((((((((“increta”[Title/Abstract] OR “increta/percreta”[Title/
Abstract])) OR “accreta”[Title/Abstract]) OR “accreta/increta/
percreta”[Title/Abstract]) OR “accreta/increta”[Title/
Abstract]) OR “accreta/percreta/increta”[Title/Abstract])) OR
(“percreta”[Title/Abstract] OR “percreta/increta”[Title/
Abstract] OR “percreta involving”[Title/Abstract] OR “per-
creta placenta”[Title/Abstract] OR “percreta presenting”[Title/
Abstract] OR “percreta, placenta”[Title/Abstract])))) AND
(((((((((“expectative”[Title/Abstract] OR “expectative
approach”[Title/Abstract] OR “expectative attitude”[Title/
Abstract] OR “expectative management”[Title/Abstract] OR
“expectative policy”[Title/Abstract] OR “expectative treat-
ment”[Title/Abstract])) OR “expectatively”[Title/Abstract])
OR “expectatory”[Title/Abstract])) OR (((“conserva-
tive”[Title/Abstract]) OR conventional[Title/Abstract]) OR
traditional[Title/Abstract])) OR ((“hysterectomy”[Title/
Abstract]) OR “hysterectomies”[Title/Abstract])) OR
(((((((((((((“surgery”[Title/Abstract]) OR “surgeries”[Title/
Abstract]) OR “resection”[Title/Abstract]) OR “resec-
tions”[Title/Abstract]) OR “resections”[Title/Abstract]) OR
“surgical”[Title/Abstract]) OR “surgically”[Title/Abstract])
OR “procedure”[Title/Abstract]) OR “procedures”[Title/
Abstract]) OR “operation”[Title/Abstract]) OR “opera-
tions”[Title/Abstract]) OR “manipulation”[Title/Abstract]) OR
“manipulations”[Title/Abstract])) OR (((((((((((((((((“treat-
ment”[Title/Abstract]) OR “treatments”[Title/Abstract]) OR
“care”[Title/Abstract]) OR “procedure”[Title/Abstract]) OR
“procedure”[Title/Abstract]) OR “procedures”[Title/Abstract])
OR “strategy”[Title/Abstract]) OR “strategies”[Title/
Abstract]) OR “usage”[Title/Abstract]) OR “way”[Title/
Abstract]) OR “management”[Title/Abstract]) OR “manage-
ments”[Title/Abstract]) OR “guidance”[Title/Abstract]) OR
“guidances”[Title/Abstract]) OR “support”[Title/Abstract])
OR “therapy”[Title/Abstract]) OR “therapies”[Title/
Abstract])).
Search Embase
(placenta:ab,ti OR placentas:ab,ti OR placentas:ab,ti) AND
(increta:ab,ti OR accreta:ab,ti OR percreta:ab,ti) AND
(expectative:ab,ti OR approach:ab,ti OR attitude:ab,ti OR
management:ab,ti OR policy:ab,ti OR treatment:ab,ti OR
expectatively:ab,ti OR expectatory:ab,ti OR conserva-
tive:ab,ti OR conventional:ab,ti OR traditional:ab,ti OR hys-
terectomy:ab,ti OR hysterectomies:ab,ti OR surgery:ab,ti OR
surgeries:ab,ti OR resection:ab,ti OR resections:ab,ti OR
resections:ab,ti OR surgical:ab,ti OR surgically:ab,ti OR pro-
cedure:ab,ti OR procedures:ab,ti OR operation:ab,ti OR
operations:ab,ti OR manipulation:ab,ti OR manipula-
tions:ab,ti OR treatment:ab,ti OR treatments:ab,ti OR
care:ab,ti OR procedure:ab,ti OR procedure:ab,ti OR proce-
dures:ab,ti OR strategy:ab,ti OR strategies:ab,ti OR
usage:ab,ti OR way:ab,ti OR management:ab,ti OR manage-
ments:ab,ti OR guidance:ab,ti OR guidances:ab,ti OR sup-
port:ab,ti OR therapy:ab,ti OR therapies:ab,ti).
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